Recent clinical trials surrounding the medication Retatrutide , specifically the 120mg formulation branded as ZPHC, suggest a significant effect on weight reduction and linked metabolic illnesses . Experts believe that this combined acting , targeting both GLP-1 and GIP receptors , could represen